Eastling Thomas Wilson
SEC insider (Form 3/4/5 filer). CIK 0001958487. Chief Financial Officer at GYRE THERAPEUTICS, INC. (GYRE). 9 reported Form 4/5 transactions since Sep 2024; latest on May 4, 2026. Located in SAN DIEGO, CA.
Companies Eastling Thomas Wilson has filed insider reports for
- GYRE THERAPEUTICS, INC. (GYRE): Officer, Chief Financial Officer
Eastling Thomas Wilson
CIK: 0001958487
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GYRE THERAPEUTICS, INC.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardIndirectStock Option (Right to Buy)
33.3K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
95.1K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
47.5K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
11.9K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
33.3K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
95.1K shares- - May 4, 2026GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
92.7K shares- - Jun 4, 2025GYRE
GYRE THERAPEUTICS, INC.
AwardDirectStock Option (Right to Buy)
26K shares- - Apr 16, 2025GYRE
GYRE THERAPEUTICS, INC.
ExerciseDirect15K shares at avg. $6.93$104K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 33,271 | - | - | Indirect |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 95,060 | - | - | Direct |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 47,530 | - | - | Direct |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 11,882 | - | - | Direct |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 33,271 | - | - | Direct |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 95,060 | - | - | Direct |
| May 4, 2026 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 92,683 | - | - | Direct |
| Jun 4, 2025 | GYRE GYRE THERAPEUTICS, INC. | Award Stock Option (Right to Buy) | 26,000 | - | - | Direct |
| Apr 16, 2025 | GYRE GYRE THERAPEUTICS, INC. | Exercise | 15,000 | $6.93 | $103,950 | Direct |
1-9 of 9 transactions